Spyre Therapeutics Financial Results
Spyre Therapeutics reported third quarter 2026 financial results, highlighting a pro forma cash position of $1.5 billion following a $400 million public offering in October. The company achieved clinical proof-of-concept for its three IBD monotherapies and is advancing combination trials with data expected in Q3 2027.
- Term
- Q3 2026
“We are increasingly well-positioned to deliver on our ambition of elevating the standard of care across immunology. In IBD, our three compelling Phase 2 monotherapy readouts and a growing body of supportive clinical evidence strengthen our conviction that our combination products have the potential to transform the treatment paradigm.”
Cameron Turtle, DPhil, Chief Executive Officer of Spyre